Clinical Trials

105 enrolled

Borderline Resectable Pancreatic Adenocarcinoma

NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT03323463 2026-04-13

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

316 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

66 enrolled

Rectal Neoplasms

NCT04745988 2026-04-09

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT03764553 2026-04-07

LyRICX

320 enrolled

Phase 2/3 Active not recruiting

Esophageal Neoplasms

NCT02135042 2026-04-03

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

685 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT04245865 2026-04-03

Toco-CoR

83 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colorectal Neoplasms

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

2 enrolled

Colonic Neoplasms

NCT00707473 2026-03-05

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 1 Active not recruiting

31 enrolled

Sinonasal undifferentiated carcinoma, Paranasal Sinus Neoplasms

NCT04522336 2026-03-05

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

16 enrolled

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

NCT04094688 2026-03-03

SOLARIS

455 enrolled 13 charts

Phase 1 Active not recruiting

Colorectal Adenocarcinoma

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

38 enrolled

Tumor-Agnostic

Neoplasms

NCT04340141 2026-02-10

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

358 enrolled

Pancreatic Neoplasms

NCT06268015 2026-02-05

BBOpCo

16 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT04762953 2026-02-03

STOPGAP

GastrointestinalGynecologic

40 enrolled

Peritoneal Neoplasms, Stomach Neoplasms

NCT04005339 2026-01-26

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

48 enrolled

Biliary Tract Neoplasms, Gastrointestinal Neoplasms

NCT00335816 2026-01-14

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

248 enrolled

Rectal Neoplasms, Colorectal Neoplasms

NCT04229459 2026-01-14

Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.

12 enrolled

Phase 1 Active not recruiting

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04523818 2026-01-14

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

25 enrolled

Clinical Stage I Gastric Cancer AJCC v8

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

42 enrolled 13 charts

Pancreatic Adenocarcinoma

NCT05504252 2026-01-07

METIMMOX-2

80 enrolled

Adenocarcinoma, Mucinous, Carcinoma, Signet Ring Cell

NCT01154920 2025-12-17

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

128 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05843188 2025-12-09

Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer

155 enrolled

Phase 1/2 Active not recruiting

Colorectal Neoplasms

NCT05627635 2025-11-10

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

20 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT05699603 2025-09-24

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

56 enrolled

Dermatologic

Keratosis, Actinic

NCT03110926 2025-09-12

Induction Chemotherapy for Locally Advanced Esophageal Cancer

40 enrolled

Esophageal Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

46 enrolled

Genitourinary

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT05610163 2025-09-08

JANUS

783 enrolled

Rectal Neoplasms

NCT03340896 2025-09-02

SALTORL

256 enrolled

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT02008656 2025-08-27

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

358 enrolled

Rectal Neoplasms

NCT00492999 2025-08-17

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

64 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT03493048 2025-08-03

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

146 enrolled

Colorectal Neoplasms

NCT03421288 2025-07-25

DANTE

677 enrolled

Stomach Neoplasms

NCT03806309 2025-07-25

TEDOPAM

106 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04594772 2025-07-02

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

32 enrolled

Pancreatic Neoplasms

NCT05253846 2025-06-10

ShorTrip

63 enrolled

Locally Advanced Rectal Cancer

NCT03073785 2025-05-25

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

46 enrolled

Phase 2/3 Active not recruiting

Pancreatic Neoplasms

NCT04068103 2025-05-07

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

635 enrolled 9 charts

Colonic Neoplasms

NCT02572141 2025-03-19

OPTICAL

738 enrolled

Colonic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast

Breast Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT02710734 2024-12-24

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

78 enrolled

Genitourinary

Urothelial Carcinoma of the Bladder

NCT00798070 2024-12-18

PANTHER

Phase 2/3 Active not recruiting

2,017 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT02919787 2024-11-20

Nordic Pancreatic Cancer Trial (NorPACT) - 1

140 enrolled

Pancreatic Neoplasms

NCT04423731 2024-11-20

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

Active not recruiting

251 enrolled

Locally Advanced Pancreatic Adenocarcinoma

NCT03018418 2024-09-19

Proton Therapy in Reducing Toxicity in Anal Cancer

14 enrolled 14 charts

Anus Neoplasms

NCT04230759 2024-09-19

RADIANCE

180 enrolled